View More Recent Stories

Nov 25, 2020 07:30AM Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting
Nov 12, 2020 07:38AM Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Nov 9, 2020 07:30AM Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
Nov 2, 2020 07:30AM Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference
Oct 7, 2020 07:06AM Stoke Therapeutics Inc. (STOK) to Move Forward With Dosing of STK-001 in Children & Adolescents in Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome
Oct 7, 2020 07:00AM Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome
Sep 9, 2020 07:30AM Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference
Aug 26, 2020 02:00PM Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Fr
Aug 17, 2020 07:30AM Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors
Aug 10, 2020 07:30AM Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Aug 4, 2020 07:30AM Stoke Therapeutics to Present at Upcoming Investor Conferences in August
Jul 9, 2020 06:07AM Stoke Therapeutics Inc. (STOK) Reports Publication of Data That Supports Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression
Jul 9, 2020 05:40AM Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating
Jun 4, 2020 08:04AM Stoke Therapeutics Inc. (STOK) Announces Julie Anne Smith to Board
Jun 4, 2020 08:00AM Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors
May 15, 2020 07:00AM Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 12, 2020 08:05AM Stoke Therapeutics Inc. (STOK) Highlights Preclinical Data that Demonstrate In-Vitro & In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency
May 12, 2020 08:00AM Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited
Mar 23, 2020 08:00AM Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates
Feb 24, 2020 08:00AM Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference
Jan 8, 2020 07:30AM Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
Jan 7, 2020 08:30AM Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
Dec 23, 2019 08:30AM Stoke Therapeutics Added to NASDAQ Biotechnology Index
Dec 8, 2019 10:00AM Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Trea
Dec 7, 2019 12:00PM Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome
Nov 26, 2019 08:30AM Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
Nov 25, 2019 11:00AM Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting
Nov 12, 2019 08:00AM Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Nov 5, 2019 08:30AM Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Oct 16, 2019 08:30AM Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources
Sep 30, 2019 08:30AM Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference
Sep 11, 2019 08:00AM Stoke Therapeutics Added to Russell 2000 and 3000 Indexes
Aug 14, 2019 08:00AM Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
Aug 6, 2019 01:39PM Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome
Aug 1, 2019 08:00AM Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
View More Recent Stories